Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 9/20 | 0.75 |
| ▸ | HSP90AB1 | P08238 | 9/20 | 0.75 |
| ▸ | NUDT1 | P36639 | 4/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | SCN4A | P35499 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.49 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.49 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.49 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | CDC7 | O00311 | 1/20 | 0.47 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7382138 | 0.86 | NUDT1 (0.66) | HSP90AA1HSP90AB1NUDT1CYP2D6MAOA | |
| SCHEMBL3950560 | 0.86 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1NUDT1KDM4EPTPN1 | |
| SCHEMBL15757653 | 0.86 | HSP90AA1 (0.67) | HSP90AA1HSP90AB1NUDT1KDM4ECDC7 | |
| SCHEMBL3945480 | 0.83 | HSP90AA1 (0.61) | HSP90AA1HSP90AB1NUDT1KDM4ECDC7 | |
| SCHEMBL15756870 | 0.83 | HSP90AA1 (0.71) | HSP90AA1HSP90AB1NUDT1KDM4ECDC7 | |
| SCHEMBL28043877 | 0.82 | HSP90AA1 (0.59) | HSP90AA1HSP90AB1NUDT1KDM4ECDC7 | |
| SCHEMBL28043914 | 0.81 | HSP90AA1 (0.67) | HSP90AA1HSP90AB1NUDT1KDM4ECDC7 | |
| SCHEMBL29417852 | 0.80 | NUDT1 (1.00) | HSP90AA1HSP90AB1NUDT1CYP2D6MAOA | |
| SCHEMBL15757374 | 0.80 | NUDT1 (1.00) | HSP90AA1HSP90AB1NUDT1CYP2D6MAOA | |
| SCHEMBL3952031 | 0.80 | HSP90AA1 (0.78) | HSP90AA1HSP90AB1NUDT1KDM4EADCY10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2925744-B1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES FOR TREATMENT OF CANCER | THOMAS HELLEDAYS STIFTELSE FOER MEDICINSK FORSKNING (SE) | 2020-12-30 | — | — | EP | disclosed |
| US-10632125-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2020-04-28 | — | — | US | disclosed |
| US-10632125-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2020-04-28 | — | — | US | disclosed |
| US-10179790-B2 | MTH1 inhibitors for treatment of cancer | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2019-01-15 | — | — | US | disclosed |
| US-10174029-B2 | Pyrimidine-2,4-diamine derivatives for treatment of cancer | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2019-01-08 | — | — | US | disclosed |
| US-10174029-B2 | Pyrimidine-2,4-diamine derivatives for treatment of cancer | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2019-01-08 | — | — | US | disclosed |
| US-20190000856-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | THOMAS HELLEDAYS STIFTELSE FOER MEDICINSK FORSKNING (SE) | 2019-01-03 | — | — | US | disclosed |
| US-20190000856-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | THOMAS HELLEDAYS STIFTELSE FOER MEDICINSK FORSKNING (SE) | 2019-01-03 | — | — | US | disclosed |
| US-10064869-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2018-09-04 | — | — | US | disclosed |
| US-20180170929-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES FOR TREATMENT OF CANCER | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2018-06-21 | — | — | US | disclosed |
| WO-2015187089-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2015-12-10 | — | — | WO | disclosed |
| WO-2015187089-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2015-12-10 | — | — | WO | disclosed |
| WO-2015187088-A1 | MTH1 INHIBITORS FOR TREATMENT OF CANCER | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2015-12-10 | — | — | WO | disclosed |
| CN-105143206-A | Pyrimidine-2,4-diamine derivatives for treatment of cancer | THOMAS HELLEDAYS STIFTELSE F R MEDICINSK FORSKNING | 2015-12-09 | — | — | CN | disclosed |
| EP-2925744-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES FOR TREATMENT OF CANCER | Thomas Helledays Stiftelse För Medicinsk Forskning (SE) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014084778-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES FOR TREATMENT OF CANCER | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2014-06-05 | — | — | WO | disclosed |
| WO-2014084778-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES FOR TREATMENT OF CANCER | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2014-06-05 | — | — | WO | disclosed |
| US-20090099183-A1 | PYRIMIDINES AND USES THEREOF | CELL THERAPEUTICS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-7419984-B2 | Pyrimidines and uses thereof | CELL THERAPEUTICS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-20040204386-A1 | Pyrimidines and uses thereof | CELL THERAPEUTICS, INC. | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180170929-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES FOR TREATMENT OF CANCER | DPYD, MTHFD1, TYMS | HSP90AA1 1619/4885HSP90AB1 1503/4885NUDT1 11/4885 |
| US-20040204386-A1 | Pyrimidines and uses thereof | LPCAT3, LPCAT1, APRT | HSP90AA1 4126/4885HSP90AB1 4236/4885NUDT1 5/4885 |
| US-10179790-B2 | MTH1 inhibitors for treatment of cancer | MTHFD1, MTHFD2, DPYD | HSP90AA1 458/4885HSP90AB1 346/4885NUDT1 27/4885 |
| US-10174029-B2 | Pyrimidine-2,4-diamine derivatives for treatment of cancer | DPYD, MTHFD1, TYMS | HSP90AA1 1619/4885HSP90AB1 1503/4885NUDT1 11/4885 |
| US-20190000856-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | MTHFD1, MTHFD2, TPMT | HSP90AA1 385/4885HSP90AB1 249/4885NUDT1 28/4885 |
| US-20090099183-A1 | PYRIMIDINES AND USES THEREOF | LPCAT3, LPCAT1, APRT | HSP90AA1 4006/4885HSP90AB1 3829/4885NUDT1 7/4885 |
| US-10632125-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | MTHFD1, MTHFD2, TPMT | HSP90AA1 385/4885HSP90AB1 249/4885NUDT1 28/4885 |
| US-10064869-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | MTHFD1, MTHFD2, TPMT | HSP90AA1 385/4885HSP90AB1 249/4885NUDT1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.